{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:02:24Z","timestamp":1791316944276,"version":"4.3.1"},"reference-count":130,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hepatobiliary & Pancreatic Diseases International"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.hbpd.2024.03.001","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T05:15:42Z","timestamp":1710566142000},"page":"441-448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Advancing immunosuppression in liver transplantation: A narrative review"],"prefix":"10.1016","volume":"23","author":[{"given":"Samuele","family":"Iesari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Laura","family":"Nava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria Elena","family":"Zais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Coubeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Ferraresso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evaldo","family":"Favi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lerut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hbpd.2024.03.001_bib0001","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s12072-020-10091-5","article-title":"Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group","volume":"14","author":"Cillo","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0002","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"Kidney Disease: improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0003","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.eng.2022.07.007","article-title":"Immunosuppression and liver transplantation","volume":"21","author":"Lerut","year":"2023","journal-title":"Engineering"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0004","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/tri.13786","article-title":"The real incidence of biliary tract complications after adult liver transplantation: the role of the prospective routine use of cholangiography during post-transplant follow-up","volume":"34","author":"Navez","year":"2021","journal-title":"Transpl Int"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0005","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.4254\/wjh.v14.i8.1541","article-title":"Long-term liver allograft fibrosis: a review with emphasis on idiopathic post-transplant hepatitis and chronic antibody mediated rejection","volume":"14","author":"Vij","year":"2022","journal-title":"World J Hepatol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0006","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jhep.2018.04.012","article-title":"Molecular profiling of subclinical inflammatory lesions in long-term surviving adult liver transplant recipients","volume":"69","author":"Londo\u00f1o","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0007","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/MOT.0000000000000127","article-title":"Everolimus in liver transplantation","volume":"19","author":"Trotter","year":"2014","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0008","first-page":"385","article-title":"The reversal of rejection in human renal homografts with subsequent development of homograft tolerance","volume":"117","author":"Starzl","year":"1963","journal-title":"Surg Gynecol Obstet"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0009","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/0140-6736(92)91840-5","article-title":"Cell migration, chimerism, and graft acceptance","volume":"339","author":"Starzl","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0010","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJM199812243392607","article-title":"Antigen localization and migration in immunity and tolerance","volume":"339","author":"Starzl","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0011","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/35105088","article-title":"Transplantation tolerance from a historical perspective","volume":"1","author":"Starzl","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0012","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(03)13175-3","article-title":"Tolerogenic immunosuppression for organ transplantation","volume":"361","author":"Starzl","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0013","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/TP.0000000000003851","article-title":"T-cell exhaustion in organ transplantation","volume":"106","author":"Angeletti","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0014","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.kint.2019.01.040","article-title":"T-cell exhaustion correlates with improved outcomes in kidney transplant recipients","volume":"96","author":"Fribourg","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0015","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0016","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3389\/fimmu.2019.02061","article-title":"The complex association of Fc\u03b3RIIb with Autoimmune Susceptibility","volume":"10","author":"Verbeek","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0017","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/ajt.16372","article-title":"Harnessing T cell exhaustion to improve solid organ transplant outcomes","volume":"21","author":"Levitsky","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0018","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0019","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1111\/ajt.15979","article-title":"Distinct peripheral blood molecular signature emerges with successful tacrolimus withdrawal in kidney transplant recipients","volume":"20","author":"Cravedi","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0020","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1111\/ajt.15870","article-title":"T cell exhaustion is associated with antigen abundance and promotes transplant acceptance","volume":"20","author":"Zou","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0021","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1001\/archsurg.134.9.971","article-title":"Excellent outcome in recipients of dual kidney transplants: a report of the first 50 dual kidney transplants at Stanford University","volume":"134","author":"Lu","year":"1999","journal-title":"Arch Surg"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0022","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1097\/01.tp.0000241104.58576.e6","article-title":"Comparison of renal allograft outcomes in combined liver-kidney transplantation versus subsequent kidney transplantation in liver transplant recipients: analysis of UNOS Database","volume":"82","author":"Simpson","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0023","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.hbpd.2021.05.002","article-title":"Symptomatic Val122del mutated hereditary transthyretin amyloidosis: need for early diagnosis and prioritization for heart and liver transplantation","volume":"20","author":"Schettini","year":"2021","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0024","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41409-018-0162-0","article-title":"Homeostatic proliferation leads to telomere attrition and increased PD-1 expression after autologous hematopoietic SCT for systemic sclerosis","volume":"53","author":"Arruda","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0025","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/SLA.0000000000002943","article-title":"Tacrolimus and single intraoperative high-dose of anti-T-lymphocyte globulins versus tacrolimus monotherapy in adult liver transplantation: one-year results of an investigator-driven randomized controlled trial","volume":"268","author":"Iesari","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0026","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T cells and human disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0027","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0028","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0029","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1097\/TP.0000000000002760","article-title":"Area under trough concentrations of tacrolimus as a predictor of progressive renal impairment after liver transplantation","volume":"103","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0030","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/lt.21185","article-title":"Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation","volume":"13","author":"Soliman","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0031","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/lt.21309","article-title":"Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors","volume":"14","author":"Bajjoka","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0032","first-page":"1747","article-title":"The impact of thymoglobulin on renal function and calcineurin inhibitor initiation in recipients of orthotopic liver transplant: a retrospective analysis of 298 consecutive patients","volume":"36","author":"Tchervenkov","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0033","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/TP.0000000000003904","article-title":"Induction therapy with antithymocyte globulin and delayed calcineurin inhibitor initiation for renal protection in liver transplantation: a multicenter randomized controlled phase II-B trial","volume":"106","author":"Nair","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0034","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/imr.12845","article-title":"mTOR signaling at the crossroads of environmental signals and T-cell fate decisions","volume":"295","author":"Huang","year":"2020","journal-title":"Immunol Rev"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0035","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/SLA.0000000000004280","article-title":"mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors","volume":"272","author":"Schnitzbauer","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0036","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.transproceed.2020.09.021","article-title":"Long-term outcomes of everolimus therapy in de novo liver transplantation: a systematic review and meta-analysis of randomized controlled trials","volume":"53","author":"Bzeizi","year":"2021","journal-title":"Transplant Proc"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0037","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/hep.31036","article-title":"Immunosuppression withdrawal in liver transplant recipients on sirolimus","volume":"72","author":"Levitsky","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0038","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/TP.0000000000002495","article-title":"mTOR inhibitor everolimus in regulatory T cell expansion for clinical application in transplantation","volume":"103","author":"Gedaly","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0039","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1097\/01.TP.0000173996.81192.F9","article-title":"Anti-CD2 monoclonal antibody and tacrolimus in adult liver transplantation","volume":"80","author":"Lerut","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.599526","article-title":"Siplizumab induces NK cell fratricide through antibody-dependent cell-mediated cytotoxicity","volume":"12","author":"Binder","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0041","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1365-4632.2010.04512.x","article-title":"Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies","volume":"49","author":"Langley","year":"2010","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0042","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0043","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/ajt.12810","article-title":"Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study","volume":"14","author":"Klintmalm","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0044","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5500\/wjt.v9.i6.103","article-title":"Therapeutic apheresis in kidney transplantation: an updated review","volume":"9","author":"Salvadori","year":"2019","journal-title":"World J Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0045","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1432-2277.2010.01176.x","article-title":"A more selective costimulatory blockade of the CD28-B7 pathway","volume":"24","author":"Poirier","year":"2011","journal-title":"Transpl Int"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0046","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.4049\/jimmunol.1601538","article-title":"First-in-human study in healthy subjects with FR104, a pegylated monoclonal antibody fragment antagonist of CD28","volume":"197","author":"Poirier","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0047","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jcph.791","article-title":"Pharmacokinetic, pharmacodynamic, and safety profile of a novel anti-CD28 domain antibody antagonist in healthy subjects","volume":"57","author":"Shi","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0048","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/ajt.15560","article-title":"A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation","volume":"20","author":"Vincenti","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0049","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/ajt.15591","article-title":"Efficacy and safety of bleselumab in kidney transplant recipients: a phase 2, randomized, open-label, noninferiority study","volume":"20","author":"Harland","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0050","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/ajt.15661","article-title":"First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody","volume":"20","author":"Espi\u00e9","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0051","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1097\/TP.0000000000003249","article-title":"Interleukin-6: an important mediator of allograft injury","volume":"104","author":"Jordan","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0052","doi-asserted-by":"crossref","first-page":"e14936","DOI":"10.1111\/ctr.14936","article-title":"Tocilizumab for treatment of chronic active antibody-mediated rejection in kidney transplant recipients","volume":"37","author":"Boonpheng","year":"2023","journal-title":"Clin Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0053","doi-asserted-by":"crossref","first-page":"e14853","DOI":"10.1111\/ctr.14853","article-title":"Tocilizumab for the treatment of chronic antibody mediated rejection in kidney transplant recipients","volume":"37","author":"Khairallah","year":"2023","journal-title":"Clin Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0054","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/lt.23481","article-title":"Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance","volume":"18","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0055","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/ajt.12667","article-title":"The role of donor-specific HLA alloantibodies in liver transplantation","volume":"14","author":"O'Leary","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0056","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/ajt.12212","article-title":"De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients","volume":"13","author":"Kaneku","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0057","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/MOT.0000000000000825","article-title":"Donor-specific antibodies in liver transplantation: challenges in diagnosis and determining clinical impact","volume":"25","author":"Kim","year":"2020","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0058","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3389\/fimmu.2020.02155","article-title":"The immunological basis of liver allograft rejection","volume":"11","author":"Ronca","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0059","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/lt.23687","article-title":"Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation","volume":"19","author":"O'Leary","year":"2013","journal-title":"Liver Transpl"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0060","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/TP.0000000000003095","article-title":"Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from The Transplantation Society Working Group","volume":"104","author":"Schinstock","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0061","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/MOT.0000000000000250","article-title":"Intravenous immunoglobulin in kidney transplantation","volume":"20","author":"Tedla","year":"2015","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0062","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/TP.0000000000001849","article-title":"Anti-CD20 blocker rituximab in kidney transplantation","volume":"102","author":"Sood","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0063","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.4254\/wjh.v7.i11.1494","article-title":"Intravenous immunoglobulins in liver transplant patients: perspectives of clinical immune modulation","volume":"7","author":"Kornberg","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0064","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.gtc.2017.01.005","article-title":"Antibody-mediated rejection after liver transplant","volume":"46","author":"Lee","year":"2017","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0065","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.humpath.2022.06.015","article-title":"Acute antibody-mediated rejection in liver transplantation: impact and applicability of the Banff working group on liver allograft pathology 2016 criteria","volume":"127","author":"Maurice","year":"2022","journal-title":"Hum Pathol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0066","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.hbpd.2022.06.019","article-title":"The critical role of therapeutic plasma exchange in ABO-incompatible liver transplantation","volume":"21","author":"Han","year":"2022","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0067","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/ajt.12520","article-title":"Impact of rituximab desensitization on blood-type-incompatible adult living donor liver transplantation: a Japanese multicenter study","volume":"14","author":"Egawa","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0068","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/ajt.13444","article-title":"ABO-Incompatible adult living donor liver transplantation under the desensitization protocol with rituximab","volume":"16","author":"Song","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0069","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/hep.28681","article-title":"Five-year histological and serological follow-up of operationally tolerant pediatric liver transplant recipients enrolled in WISP-R","volume":"65","author":"Feng","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0070","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ekir.2022.01.1074","article-title":"Evaluation of clazakizumab (anti-interleukin-6) in patients with treatment-resistant chronic active antibody-mediated rejection of kidney allografts","volume":"7","author":"Jordan","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0071","doi-asserted-by":"crossref","first-page":"10511","DOI":"10.3389\/ti.2022.10511","article-title":"European guideline for the management of kidney transplant patients with HLA antibodies: by the European Society for Organ Transplantation Working Group","volume":"35","author":"Mamode","year":"2022","journal-title":"Transpl Int"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0072","doi-asserted-by":"crossref","first-page":"e24853","DOI":"10.1097\/MD.0000000000024853","article-title":"Effect of rituximab dose on induction therapy in ABO-incompatible living kidney transplantation: a network meta-analysis","volume":"100","author":"Lee","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0073","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.krcp.2015.11.001","article-title":"Comparison of clinical outcomes between ABO-compatible and ABO-incompatible spousal donor kidney transplantation","volume":"35","author":"Park","year":"2016","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0074","doi-asserted-by":"crossref","first-page":"e729","DOI":"10.1097\/TXD.0000000000001180","article-title":"Rituximab desensitization in liver transplant recipients with preformed donor-specific HLA antibodies: a Japanese nationwide survey","volume":"7","author":"Akamatsu","year":"2021","journal-title":"Transplant Direct"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0075","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.1038\/s41467-021-25745-7","article-title":"C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates","volume":"12","author":"Schmitz","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0076","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.it.2021.08.001","article-title":"Contributing authors. C3-targeted therapy in periodontal disease: moving closer to the clinic","volume":"42","author":"Hajishengallis","year":"2021","journal-title":"Trends Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0077","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/TP.0000000000000592","article-title":"A phase I\/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients","volume":"99","author":"Vo","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0078","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1111\/ajt.15397","article-title":"Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies","volume":"19","author":"Glotz","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0079","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/tri.12396","article-title":"Antibody-mediated rejection despite inhibition of terminal complement","volume":"27","author":"Bentall","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0080","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/ajt.16420","article-title":"Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients","volume":"21","author":"Patel","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0081","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1056\/NEJMoa1612567","article-title":"IgG endopeptidase in highly sensitized patients undergoing transplantation","volume":"377","author":"Jordan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0082","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1111\/ajt.16754","article-title":"Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients","volume":"21","author":"Kjellman","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0083","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/bjs\/znac293","article-title":"Enzymatic blood group conversion of human kidneys during ex vivo normothermic machine perfusion","volume":"110","author":"MacMillan","year":"2023","journal-title":"Br J Surg"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0084","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/lt.25948","article-title":"Regulatory T cell therapy following liver transplantation","volume":"27","author":"Yu","year":"2021","journal-title":"Liver Transpl"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0085","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0086","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1073\/pnas.0910620107","article-title":"FoxP3+ regulatory T cells essentially contribute to peripheral CD8+ T-cell tolerance induced by steady-state dendritic cells","volume":"107","author":"Schildknecht","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0087","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(20)30167-7","article-title":"Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1\/2A trials","volume":"395","author":"Sawitzki","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0088","doi-asserted-by":"crossref","first-page":"e01099","DOI":"10.1002\/cti2.1099","article-title":"Regulatory T cells in solid organ transplantation","volume":"9","author":"Atif","year":"2020","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0089","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.719954","article-title":"Regulatory T-cell therapy in liver transplantation and Chronic Liver Disease","volume":"12","author":"Hann","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0090","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/MOT.0000000000000670","article-title":"Current state of organ transplant tolerance","volume":"24","author":"Rickert","year":"2019","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0091","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fimmu.2019.00043","article-title":"Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity","volume":"10","author":"Romano","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0092","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.535012","article-title":"Clinical and basic research progress on Treg-induced immune tolerance in liver transplantation","volume":"12","author":"Ni","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0093","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1111\/j.1600-6143.2008.02300.x","article-title":"New insights into mechanisms of spontaneous liver transplant tolerance: the role of Foxp3-expressing CD25+CD4+ regulatory T cells","volume":"8","author":"Li","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0094","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3389\/fimmu.2017.01313","article-title":"Avidity and bystander suppressive capacity of human regulatory T cells expressing de novo autoreactive T-cell receptors in type 1 diabetes","volume":"8","author":"Yeh","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0095","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/ajt.13456","article-title":"Discarded human thymus is a novel source of stable and long-lived therapeutic regulatory T cells","volume":"16","author":"Dijke","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0096","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.3389\/fimmu.2017.01844","article-title":"Minimum information about T regulatory cells: a step toward reproducibility and standardization","volume":"8","author":"Fuchs","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0097","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1182\/blood-2006-06-027409","article-title":"Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion","volume":"108","author":"Hoffmann","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0098","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41598-017-17981-z","article-title":"Optimizing human Treg immunotherapy by Treg subset selection and E-selectin ligand expression","volume":"8","author":"Donnelly","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0099","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.21037\/atm-21-3812","article-title":"Study on the preparation and function of regulatory T cells from human peripheral blood","volume":"9","author":"Zuo","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0100","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1038\/s41598-018-25574-7","article-title":"A phase I clinical trial with ex vivo expanded recipient regulatory T cells in living donor kidney transplants","volume":"8","author":"Mathew","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0101","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41573-019-0041-4","article-title":"Next-generation regulatory T cell therapy","volume":"18","author":"Ferreira","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0102","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41422-020-0324-7","article-title":"Transcriptional and epigenetic basis of Treg cell development and function: its genetic anomalies or variations in autoimmune diseases","volume":"30","author":"Ohkura","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0103","doi-asserted-by":"crossref","first-page":"e3161","DOI":"10.1371\/journal.pone.0003161","article-title":"Clinical grade Treg: GMP isolation, improvement of purity by CD127 depletion, Treg expansion, and Treg cryopreservation","volume":"3","author":"Peters","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0104","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/scd.2008.0253","article-title":"Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect","volume":"18","author":"Fischer","year":"2009","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.883855","article-title":"Untangling the knots of regulatory T cell therapy in solid organ transplantation","volume":"13","author":"Orozco","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0106","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhepr.2019.08.001","article-title":"Liver homing of clinical grade Tregs after therapeutic infusion in patients with autoimmune hepatitis","volume":"1","author":"Oo","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0107","first-page":"8","article-title":"Forkhead box P3 (FOXP3) mRNA expression immediately after living-donor liver transplant","volume":"7","author":"Sakamoto","year":"2009","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0108","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1097\/TP.0b013e318188d3e6","article-title":"FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal","volume":"86","author":"Pons","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0109","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/hep.28459","article-title":"A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation","volume":"64","author":"Todo","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661875","article-title":"Antigen-specific regulatory T cell therapy in autoimmune diseases and transplantation","volume":"12","author":"Selck","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0111","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1084\/jem.137.5.1142","article-title":"Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution","volume":"137","author":"Steinman","year":"1973","journal-title":"J Exp Med"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0112","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.552988","article-title":"Tolerogenic dendritic cells: the pearl of immunotherapy in organ transplantation","volume":"11","author":"Zhuang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0113","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3389\/fimmu.2020.01326","article-title":"Progress in liver transplant tolerance and tolerance-inducing cellular therapies","volume":"11","author":"Du","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0114","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1365-2249.1996.d01-779.x","article-title":"Dendritic cells and tolerance induction","volume":"105","author":"Steptoe","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0115","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1182\/blood-2002-09-2712","article-title":"Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells","volume":"101","author":"Sato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0116","doi-asserted-by":"crossref","first-page":"14985","DOI":"10.1038\/s41598-018-33248-7","article-title":"Comparative transcriptomic profile of tolerogenic dendritic cells differentiated with vitamin D3","volume":"8","author":"Navarro-Barriuso","year":"2018","journal-title":"dexamethasone and rapamycin. Sci Rep"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0117","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.599623","article-title":"Vitamin D3-induced tolerogenic dendritic cells modulate the transcriptomic profile of T CD4+ cells towards a functional hyporesponsiveness","volume":"11","author":"Navarro-Barriuso","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0118","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.4049\/jimmunol.0803345","article-title":"1,25-dihydroxyvitamin D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype","volume":"182","author":"Sz\u00e9les","year":"2009","journal-title":"J Immunol"},{"issue":"188","key":"10.1016\/j.hbpd.2024.03.001_bib0119","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-3-540-71029-5_10","article-title":"Use of rapamycin in the induction of tolerogenic dendritic cells","author":"Fischer","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0120","doi-asserted-by":"crossref","first-page":"15087","DOI":"10.1038\/s41598-017-15569-1","article-title":"Tolerogenic dendritic cells are efficiently generated using minocycline and dexamethasone","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0121","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.coi.2014.12.009","article-title":"Suppression of antigen presentation by IL-10","volume":"34","author":"Mittal","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0122","doi-asserted-by":"crossref","first-page":"27158","DOI":"10.1074\/jbc.M115.682708","article-title":"Interleukin 10 (IL-10)-mediated Immunosuppression: March-I induction regulates antigen presentation by macrophages but not dendritic cells","volume":"290","author":"Mittal","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0123","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3389\/fimmu.2018.00350","article-title":"Mechanisms of tolerance induction by dendritic cells in vivo","volume":"9","author":"Hasegawa","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0124","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.molimm.2020.06.028","article-title":"B cell modulation strategies in the improvement of transplantation outcomes","volume":"125","author":"Afzali","year":"2020","journal-title":"Mol Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0125","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.611795","article-title":"Immunosuppressive mechanisms of regulatory B cells","volume":"12","author":"Catal\u00e1n","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0126","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110728","article-title":"Human IL-10-producing B cells have diverse states that are induced from multiple B cell subsets","volume":"39","author":"Glass","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0127","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1615\/CritRevImmunol.2015012558","article-title":"Interleukin 35-producing B cells (i35-Breg): a new mediator of regulatory B-cell functions in CNS autoimmune diseases","volume":"35","author":"Egwuagu","year":"2015","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0128","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1183714","article-title":"Human granzyme B regulatory B cells prevent effector CD4+CD25- T cell proliferation through a mechanism dependent from lymphotoxin alpha","volume":"14","author":"Sailliet","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0129","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.molimm.2019.02.009","article-title":"PD-1-expressing B cells suppress CD4+ and CD8+ T cells via PD-1\/PD-L1-dependent pathway","volume":"109","author":"Wang","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1016\/j.hbpd.2024.03.001_bib0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/imr.12933","article-title":"Regulatory B cells: TIM-1, transplant tolerance, and rejection","volume":"299","author":"Cherukuri","year":"2021","journal-title":"Immunol Rev"}],"container-title":["Hepatobiliary & Pancreatic Diseases International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499387224000407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499387224000407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T08:29:55Z","timestamp":1719649795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499387224000407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":130,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1499387224000407"],"URL":"https:\/\/doi.org\/10.1016\/j.hbpd.2024.03.001","relation":{},"ISSN":["1499-3872"],"issn-type":[{"value":"1499-3872","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing immunosuppression in liver transplantation: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Hepatobiliary & Pancreatic Diseases International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hbpd.2024.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}